- cross-posted to:
- politics@lemmy.world
- health@lemmy.world
- cross-posted to:
- politics@lemmy.world
- health@lemmy.world
More Americans with diabetes will get a break on their insulin costs in 2024.
Sanofi is joining the nation’s two other major insulin manufacturers in offering either price caps or savings programs that lower the cost of the drugs to $35 for many patients. The three drugmakers are also drastically lowering the list prices for their products.
The moves were announced in the spring, but some didn’t take effect until January 1.
Drugmakers have come under fire for years for steeply raising the price of insulin, which is relatively inexpensive to produce. The inflation-adjusted cost of the medication has increased 24% between 2017 and 2022, and spending on insulin has tripled in the past decade to $22.3 billion in 2022, according to the American Diabetes Association.
Some 8.4 million Americans rely on insulin to survive, and as many as 1 in 4 patients have been unable to afford their medicine, leading them to ration doses – sometimes with fatal ramifications, according to the association.
The whole argument is absurd because neither one did anything, the companies themselves did this voluntarily and can switch it back at any time because there’s no federal statute or regulation to stop them
You didn’t read the article did you?
They cite multiple factors but the largest seems to be a change to the way Medicare rebates are paid. Starting Jan 1st, this move allows them to pay less rebates to Medicare based on how they’re calculated and will save the companies millions. So yes… it’s actually directly based on the Biden administration changes.